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Abstract 
The purpose of this review is to evaluate the credibility of modeled claims for cost-effectiveness studies published in the Journal of 
Medical Economics (JME) in the period January 2015 to December 2015. Credibility is assessed in terms of the standards of normal 
science. Are the claims made capable of falsification and replication?  Following the PRISMA-P recommendations, abstracts of all 
papers published in the JME were evaluated by both authors independently against a MeSH terms checklist: cost, cost-effectiveness, 
cost-utility, outcomes, QALY and Markov. A total of 32 studies were identified. A systematic review of each study was then evaluated. 
The consensus was that all studies be included in the review. Each study was judged against four criteria: (i) Is the model capable of 
generating evaluable claims? (ii) did the author(s) attempt to generate evaluable claims? (iii) did the author(s) suggested how the 
claims might be evaluated? and (iv) did the author(s) caution readers as to the implications of generating non-evaluable clams for 
the credibility of the analysis? None of the studies presented their claims or projections in an evaluable form and none suggested how 
they might be evaluated. None met the standards of normal science. The claims made for cost-effectiveness were either impossible to 
verify, or if potentially verifiable, were not presented in an evaluable form. The studies lacked credibility. There was no basis for 
assessing whether the claims were right or even if they were wrong. The JME is not alone. As part of an ongoing systematic review 
program, covering the leading journals and focusing on chronic condition areas, it is clear that the majority of cost-effectiveness 
papers also fail the test of credibility. Of course, it might be that the consensus opinion among practitioners is that non-evaluable 
projections are acceptable. Evidence is not discovered, but is constructed through models and simulations. This lack of scientific 
credibility is a major concern. If medical economics is to advance through the formulation and testing of hypotheses, then editors of 
journals should consider whether or not to set standards for the acceptance of publications to include the requirement for evaluable 
claims and the results of claims assessment. If this is not acceptable, then it should be made clear that published papers are simply 
imaginary worlds or thought experiments.   
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Introduction 
In a recent supplement to the Journal of Medical Economics 
(JME), the case was put forward that if claims for the impact 
of products and devices on costs and outcomes in health care 
systems are to be accepted, then they should meet the 
standards expected in ‘normal science’ 1 2 3 4 5. The argument 
was made that if modeled claims are to be credible, practical, 
and useful in formulary decisions, then the only acceptable 
modeled claims in formulary submissions are those that are 
evaluable in a timeframe relevant to the needs of a formulary 
committee. If claims do not meet this standard, they should 
be rejected. Given the experience of modeled claims made to 
the National Institute for Health and Care Evidence (NICE) in 
the UK, the current situation in the US, and other developed 
economies, a new research agenda was proposed. This  
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agenda would focus on the evaluable impact of products and 
devices on patient outcomes, resource utilization, and the 
costs of health care delivery. Central to this research agenda 
would be the recognition that unless a modeled study yields 
evaluable claims that are reproducible across multiple 
healthcare settings, the model has no credibility when set 
against the standards of normal science. There should be an 
acceptance that the standards of normal science apply to the 
process of discovering new facts in health care decision 
making 6.   
 
The purpose of this systematic review, which is part of a 
program being undertaken at the College of Pharmacy, 
University of Minnesota to evaluate the credibility of cost-
effectiveness claims in leading journals and in chronic 
conditions, is to assess cost-effectiveness claims published in 
the JME during 2015. A review of papers published in 
Pharmacoeconomics during 2015 has ready been published7.  
As detailed in the PharmacoEconomics review, if a modeled 
cost-effectiveness claim is to meet the standards of normal 
science then it has to (i) involve the construction of an 
empirically evaluable coherent theory and (ii) facilitate the 
testing of hypotheses through experimentation or 
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observation. These are standards that have been in place 
since the 17th century and demarcate science from 
pseudoscience; the demarcation between natural selection 
and intelligent design 8.  
 
The purpose of these ongoing reviews is to determine 
whether published studies meet the standards of normal 
science or whether they reflect a relativist position that, 
through consensus, believes other standards should apply in 
supporting value claims for pharmaceutical products and 
devices 6. 9  10 It is not the purpose of the research program 
to deny constructed modeled or simulated claims. Rather, in 
focusing on the claims, irrespective of the perceived merits of 
the model or simulation generating those claims, if they fail 
the standards of falsification and replication, then they are 
not credible inputs for health care decision making 11 12. The 
standards of normal science are absolute. Constructed 
evidence and untestable projected claims are not acceptable. 
 
Methods 
Following the PRISMA-P recommendations, abstracts of all 
papers published in the JME in the period January 2015 to 
December 2015 were evaluated by both authors against a 
MeSH terms checklist: cost, cost-effectiveness, cost-utility, 
outcomes, QALY and Markov 13. A total of 32 studies were 
identified. Each study was then carefully reviewed and 
evaluated. The consensus was that all studies be included in 
the review. (see references 22 through 53).  
 
Four questions were considered in the assessment of 
whether the modeled cost-effectiveness studies presented 
met the standards of normal science: 
• Is the model capable of generating evaluable 
claims? 
• Did the author(s) attempt to generate evaluable 
claims? 
• Did the authors suggest how the claims might be 
evaluated? 
• Did the author(s) caution readers as to the 
implications of generating non-evaluable claims for 
the credibility of the analysis? 
An evaluable claim was defined as one that had the potential 
to be assessed empirically in a timeframe relevant to the 
needs of a formulary committee (ideally a period of 2 to 3 
years). This period was chosen because a evaluable claim was 
seen as provisional; a point that was made over 10 years ago 
in formulary guidelines proposed for WellPoint Inc. (now 
known as Anthem Inc.) in the US 14. A product or device 
would, following these guidelines, be accepted by a formulary 
committee for formulary listing, but subject to an agreement 
with the manufacturer to report back to the committee with 
evidence to support the claims made. There was no 
restriction on the type of claim. These claims could be for 
product comparative effectiveness, for the impact of the 
product on resource utilization or some combination of these 
to support a claim for incremental cost-effectiveness. The 
claim for comparative effectiveness could encompass clinical 
endpoints as well as those captured as patient reported 
outcomes. Irrespective of the claim made, this was assessed 
in the context of the claim providing feedback to a formulary 
committee to support ongoing disease area and therapeutic 
reviews.  
 
If these credibility standards are accepted, then the 
responsibility is on the authors of a modeled claim or 
simulation to structure their analysis to generate evaluable 
claims. If claims are put in cost-utility terms, then it has to be 
shown how those claims might be evaluated. If claims are 
expressed in adverse events avoided or if the claims were 
disaggregated by a base-line risk of stroke, again it should be 
shown how those claims are to be assessed.  
 
In judging whether or not a model might support evaluable 
claims, even if the possibility is not considered by the 
authors(s), three characteristics of a model are important. 
These are: (i) the modeling framework, (ii) the choice of 
primary outcome measure; and (iii) the time frame for the 
model. A Markov or discrete event simulation model with a 
lifetime perspective and with discounted cost per quality 
adjusted life year (QALY) claims as the primary endpoints 
would be one that would be impossible to evaluate. Against 
this, a simple, trial-based decision model with a timeframe of 
12 to 18 months with claims expressed in clinical terms 
(including PROs) and resource utilization endpoints would, 
given access to readily available data sources in the US, be 
open to hypothesis testing, feedback to a formulary 
committee and replication in other target populations. 
 
The important point to note is that a modeled claim is not to 
be judged on the reasonableness or otherwise of the 
assumptions of the model. Certainly the model would be 
expected to cover comparator products, or least the key 
comparators, and to identify the target population for the 
claims. The NICE reference case model is of particular 
interest 15. The reference case is important in health 
technology assessment because it has been adopted as the 
preferred format for formulary submissions in a number of 
single payer health systems 16 17. It has also influenced in the 
US the Academy of Managed Care Pharmacy (AMCP) Format 
for Formulary Submissions 18 . Through standards established 
by professional groups such as the International Society for 
Pharmacoeconomics and Outcomes Research (ISPOR) and the 
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adoption of quality check lists such as CHEERS, the reference 
case standard has had a significant effect on the widespread 
adoption of constructed, lifetime cost-per-QALY models to 
generate non-evaluable claims for product 
performance 19 20 21. This acceptance is such that cost-per-
QALY claims dominate the literature. Unfortunately, little 
attention is given as to how these claims might be evaluated 
for formulary decisions or whether formulary decision makers 
are actually interested in these claims  
 
Results 
The main findings from the review of the 32 studies (Table 1) 
are: 
• None of the studies presented their results in a 
evaluable form. 
• None of the studies proposed a protocol or 
otherwise suggested how the claims might be 
evaluated. 
• None of the studies addressed the issue of 
replication and the possibility of evaluating the 
claims for other target populations. 
• 15 of the studies (47%) presented their results in a 
timeframe that excluded any possible  evaluation: 28 
years – 1 study; 30 years – 2 studies; 40 years – 3 
studies; 50 years – 1 study; lifetime of subject cohort 
– 9 studies. 
• None of the studies with results reported for 
timelines too long to support evaluable claims 
cautioned the reader than the claims were not 
evaluable and the possible implications of this for 
the credibility of the modeled results. 
• One lifetime study (not included above) projected 
results over such a short survival span that evaluable 
claims were possible. 
• 12 of the studies presented results in a period short 
enough (< 2 years) to support presenting evaluable 
claims. 
• 3 of the studies presented results in a period (2 to 5 
years) that could have been reformulated to 
generate claims for evaluation over a 2 year 
timeframe. 
• QALYs were the primary endpoint in 19 studies. 
• In the studies with a timeframe that excluded any 
possible evaluation all used cost-per-QALY as a 
primary endpoint. 
• 30 of the 32 studies (94%) were supported by a 
pharmaceutical manufacturer 
• In the 30 studies supported by a manufacturer, 29 
(97%) reported results that supported the sponsor’s 
product. 
 
Discussion 
Three findings stand out from this systematic review: 
• 15 of the 32 studies published in JME reported 
results in a timeframe that was clearly incapable of 
generating evaluable claims; 
• None of the studies published in the JME proposed 
evaluable claims or how their claims might be 
evaluated; and 
• An overwhelming proportion of studies in the JME 
(91%) were sponsored by manufacturers and 
supported the sponsor’s product. 
Even though 12 of the studies had the potential for 
evaluation, given the model time frame, it seems clear that 
the authors of these studies never intended the claims to be 
subject to empirical evaluation. The projections were to be 
taken at face value and, given the fact that virtually all were 
sponsored by a manufacturer, were intended (presumably) to 
influence formulary decisions. 
 
From the decision-makers perspective, the claims put 
forward were driven by assumption. The models were 
extensively documented, data sources clearly referenced and 
limitations clearly set out. Emphasis was placed on the 
structure of the model, the application of relatively 
sophisticated techniques in decision modeling and state 
transitions, with appropriate account taken of uncertainty 
and likelihood claims for cost-effectiveness. What was 
missing was any attempt to translate the modeled claims to 
evaluable hypotheses and suggest protocols to support 
claims assessment, feedback to decision makers and 
replication. 
 
The most egregious examples of modeled claims were the 15 
studies that, in their choice of timeframe, were clearly 
incapable of generating evaluable hypotheses. Irrespective of 
whether or not decision makers were expected to take these 
claims seriously, the fact is that they met recommended 
standards for modeling. The IMS CORE Diabetes model and 
the Cardiff Diabetes model are well regarded and accepted 
model frameworks and were used in five studies 22 23. The 
three studies using the IMS CORE diabetes model generated 
claims for both one-year and 30 years 29 30 41. In the Gupta et 
al. study30 the projections for India, Indonesia, and Saudi 
Arabia focused on life expectancy, cost, and complications 
related to diabetes and cost per QALY. While the analysis 
supported switching to the sponsor’s product, the claims over 
30 years were clearly not evaluable. The Home et al. study 
also used the IMS CORE Diabetes model and matched the 
Gupta et al. analysis in generating projections for 1-year and 
30-year timeframes 29. In this case, five countries were 
considered, including Mexico, South Korea, India, Indonesia, 
and Algeria, to assess the impact of starting insulin detemir in 
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insulin-naïve people with type 2 diabetes. The 30-year 
projections considered life expectancy, costs, complications, 
and cost-effectiveness. The 1-year model focused on 
treatment costs and quality of life. Initiating therapy with 
insulin detemir, the sponsor’s product was found to be cost-
effective in all countries. The Huetson et al.. lixisenatide type 
2 diabetes analysis for Norway took a similar lifetime 
perspective, reporting on weight loss, lifetime healthcare 
costs, and QALYs. The modeled results supported the 
sponsor’s product41.   Two studies used the Cardiff diabetes 
model in Chinese populations 47 52. The Gu et al. study for 
saxagliptin and the Deng et al. model for exenatide both 
reported results for a 40 year  timeframe. While no funding 
was reported for the Deng et al. study, the Gu et al. study 
supported the sponsor’s product.  
 
The IMS CORE model and the Cardiff model simulations for 
time periods of 30 years and 40 years respectively are quite 
clearly not intended to generate comparative product claims 
that are evaluable, let al.one replicable in target populations. 
There is not the remotest chance that the claims made over 
these timespans could ever be evaluated. The claims could, of 
course be taken at face value and as ‘indicative’ of implicit 
product superiority without any risk of contradiction, except 
for a possible competitive claim based on a competing long-
term diabetes model. Such a clash of imaginary diabetic 
worlds is unlikely to resolve the debate. With what may seem 
an absurd timeframe, competing claims would still have no 
chance of ever being evaluated by an appeal to real world 
experimentation. Indeed, from a decision maker’s 
perspective, any appeal to accept these 30 and 40 year claims 
at face value overlooks the fundamental point: we will never 
know whether they are right or even if they are wrong.  
 
The same argument also applies to the other 10 published 
studies that have modeled claims over extended periods. 
These range from 28 years in the case of the Attard et al. 
study  of pertuzumab, the Cure et al. study of sofosbuvir 
which followed a simulated cohort of 10,000 respondents 
until they reached 80 years of age, and the Meier et al. 
updated analysis of quadrivalent influenza vaccination (QIV) 
that, in one-year cycles, utilized a multi-cohort static Markov 
model that followed the youngest patient until they reached 
100 years of age 27 43 44.  
 
Other long-term models were also potentially misleading. As 
one example, consider the flingolimod multiple sclerosis 
model for England 32. The model utilizes a 50-year horizon 
lifetime cost-per QALY structure involving 21 health states. 
While the authors justify their choice of model as subscribing 
to the models used in NICE single appraisal submissions, the 
model is clearly not designed to generate evaluable 
hypotheses and the replication of study results. Even with the 
NICE seal of approval (and the presumed acceptance by NICE 
that modeling imaginary worlds for 50-year time horizon is 
the technology assessment standard), the assumption-based 
claims are clearly nonsensical unless one is prepared to argue 
that they, sort of, reflect an expected future reality.  A reality 
which is well outside any attempt at, say, GDP predictions or 
even demographic projections. 
 
Against these examples of long-term or lifetime models, 
there are instances where a lifetime framework might make 
sense. Consider the yttrium-90 inoperable colorectal liver 
metastases model 46 . The survival profiles for those 
introduced to the therapy as well as those receiving best 
supporting care are so limited that a lifetime model may 
capture the relevant endpoints for a comparative assessment 
to be reported and replicated. Establishing evaluable claims is 
clearly possible given the modeled result that yttrium-90 is 
projected to result in a mean undiscounted life expectancy of 
2.38  years compared to 1.03 years for best supportive care. 
There are also what may be described as intermediate 
models with claims expressed in a 2-year to a 5-year time 
frame. These include the Penn et al. 5-year model of 
cardiovascular biomarkers and the Thibault et al. 3-year 
model of memantine in Alzheimer’s disease 37 51. While these 
timeframes are probably not suited to effective reporting to 
formulary committees as part of ongoing disease area and 
therapeutic class reviews, there is a potential for these 
models to be reconsidered and claims expressed in a shorter 
and more evaluable timeframe. 
 
Finally, there are models predicated on a ≤ 2-year time frame. 
These clearly have the potential for evaluable claims, 
evaluation, and replication. They include the Evans et al. 12-
month cost per QALY model of insulin degludec in the UK, the 
Lin et al. model of psychiatric relapse and recidivism in 
schizophrenia, through the 24 week Hofmacher and Borg et 
al. iron deficiency model, the O’Day 2-year model of 
relapsing-remitting multiple sclerosis in Sweden and the Toor 
et al. 1-year model of ulcerative colitis in Canada22 28 38 32 36 . 
 
Even so, without being unduly alarmist, the fact that 30 out of 
32 studies were supported by manufacturers, and with 29 of 
these studies supporting the manufacturer’s product must be 
a concern. The potential for bias in manufacturer sponsored 
modeled cost-effectiveness studies was recognized by the 
New England Journal of Medicine (NEJM) over 20 years 
ago 24. As a result, manufacturer sponsored studies, or 
studies where there was a potential conflict of interest in 
authorship, were excluded from consideration and 
publication in NEJM. Even so, if there was no apparent 
conflict of interest, the NEJM was still prepared to publish 
modeled claims that did not meet the standards of normal 
science. 
Commentary FORMULARY EVALUATIONS 
 
http://z.umn.edu/INNOVATIONS                      2016, Vol. 7, No. 2, Article 16                            INNOVATIONS in pharmacy   5 
 
 
Unfortunately, attempts to assess possible bias in the choice 
of model and the specification of inputs are likely to be a 
fruitless exercise if the outcome is just another set of 
unevaluable claims. If there are concerns about bias and 
subscribing to the standards of normal science, there should 
be an appeal to the evidence. Competing claims can be 
evaluated through either retrospective or prospective 
observational evaluations, with the opportunity to replicate 
claims across a range of target populations.  
 
A Relativist Consensus? 
We might reasonably ask how, after some 30 years of 
promoting pharmacoeconomics and the modeling of 
competing claims, we have ended up sponsoring and 
publishing modeled claims that are either patently 
unevaluable, or potentially evaluable that are presented in a 
form that is unevaluable? One possibility is that consciously 
or not, pharmacoeconomics has put to one side application of 
the standards of normal science in favor of a relativist 
position that accepts modeled claims as a useful input to 
formulary decisions, irrespective of whether or not there is 
any empirical evidence to support the claims that are made. 
In other words, the adoption of an equivalence position that 
maintains that evidence is constructed within a particular 
social community. The process of discovering new facts is put 
to one side. If this argument is accepted, then what passes for 
a scientific research program in pharmacoeconomics, is a 
focus on rhetoric, persuasion and authority. The success of 
this program does not depend on its ability to generate new 
knowledge though the discovery of new facts and to 
reproduce or reject prior claims, but on its ability to mobilize 
the support of the community. To the relativist leaders of this 
community, normal science is not a way of coming to grips 
with reality.  
 
Truth is consensus.  
Whether or not one agrees that the thought leaders in 
pharmacoeconomics and the authors of many ISPOR 
standards subscribe to a relativist position, the fact remains 
that a substantial percentage of modeled claims for cost-
effectiveness are accepted by journals such as the JME, Value 
in Health and PharmacoEconomics clearly fail the standards 
that are accepted in normal science. This position is 
compounded by agencies such as PHARMAC in New Zealand 
and Health Information and Quality Authority in Ireland in 
their adoption of the NICE reference case framework for 
manufacturer’s submissions 25 26. The  Pharmaceutical 
Benefits Advisory Committee (PBAC) in Australia and the 
Academy of Managed Care Pharmacy (AMCP) with their 
Format for Formulary Submissions also encourage product 
claims built on simulations with no evaluable claims  27 28.  
In contrast to pharmacoeconomics, in mainstream 
economics, there is an appreciation of the scientific method, 
the formulation of hypotheses, the process of conjecture and 
refutation, and a commitment to the discovery of new facts. 
Even so, the issue of reproducibility is still of concern. In a 
recent paper, Camerer et al.29 evaluated the replicability of 
microeconomic laboratory experiments. They found that in 
attempting to replicate 18 studies there was a significant (5%) 
effect in the same direction in only 61% of the studies and on 
average a replicated effect size of 66% of the original.  
 
One possible reason for accepting a relativist position is that, 
at least outside of the US, the data environment is so limited 
that, unless considerable resources are expended, it is 
impossible to evaluate evaluable claims. The second best 
position (and least costly) is to accept modeled claims at face 
value, justifying our acceptance of those claims on the 
apparent sophistication of the model and our belief that it is a 
‘reasonable’ reflection or representation of reality. This 
argument falls at the first hurdle. As Ellis and Silk point out in 
their critique of string theorists’ claims that, the inherent 
elegance of a model should be sufficient for its acceptance 
without the need to evaluate evaluable claims 30. Adopting 
this position avoids the critical question: what potential 
observational evidence would persuade us that the theory (or 
decision model) is wrong and lead us to abandoning it? If 
there is none, then it is not a scientific theory. As Wolfgang 
Pauli stated, in situations where an argument cannot be 
falsified by experiment, “This isn’t right. This isn’t even 
wrong” 31.  
 
A Backlog of Unevaluable Claims 
Unfortunately, the accumulation of untested and unevaluable 
claims appears to be the hallmark of pharmacoeconomics. 
Few of the hundreds, if not thousands, of modeled 
projections published in the past 25 to 30 years have ever 
being exposed to evaluation, even though there has been 
ample time for modeled claims to be formulated empirically 
and evaluated. This observation applies equally well to 
modeled claims submitted to health technology assessment 
agencies. In the case of the PBAC in Australia, for example, 
where guidelines have been a requirement for formulary 
assessment for almost 25 years, there no evidence to suggest 
that, for those modeled claims that have been submitted and 
accepted to justify product listing on the Pharmaceutical 
Benefits Scheme, that there have been any attempts to 
evaluate and replicate those claims in target patient 
populations. It has never been suggested that a protocol 
should accompany the modeled cost-effectiveness claim to 
facilitate evaluation in target treating population, let alone a 
commitment to the replication of claims. 
 
For those who advocate non-evaluable simulated projections 
to support formulary decisions, their case is further 
weakened by the growing evidence (and concern) over the 
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lack of attempts to replicate empirical results and the inability 
to reproduce results in medicine, neuroscience, genetics and 
psychology. To the extent non-reproducible clinical results 
are factored into the assumptions supporting modeled claims 
for cost-effectiveness, the less credible are the claims based 
on those models. The fact that the claims are all too often 
non-evaluable merely adds to these concerns.  
 
Conclusions 
The present review has focused on modeled cost-
effectiveness claims. A similar evaluation could be directed at 
other subject areas, in particular burden of illness and cost of 
illness studies. While these rely, for the most part, on 
retrospective data, there are modeled claims for lifetime 
costs of illness which would likely fail the required standards. 
Even so, irrespective of whether the claim is defended on the 
grounds that it ‘reflects reality’, the standards for falsification 
and replication still apply. Authors and editors should 
recognize the importance, in judging the worth of modeled 
projections, that instead of taking them at face value, they 
should conform to the scientific method and support 
falsification and replication. Otherwise, we will face an 
ongoing accumulation of studies that lack credibility. 
 
If the premise of this review is accepted, that claims for cost-
effectiveness should meet the standards of normal science, 
then the editors of journals such as the JME need to consider 
whether it is possible to formulate an editorial policy that 
supports an ongoing process of developing and evaluating 
evaluable claims. A policy should recognize the importance of 
replication in establishing trust in scientific knowledge. This 
review has demonstrated that there are a number of 
instances where short-term modeled evaluations are capable 
of generating evaluable predictions. Journals such as the JME 
could take the next steps of encouraging authors to put 
claims in an evaluable form, to propose a protocol for claims 
assessment and, if possible, and report on the results of the 
claims evaluation.  
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Table 1: Imaginary Worlds - Cost-Effectiveness Studies In The Journal Of Medical Economics January 2015 To December 2015 
 
Paper 
(author) 
Target Population and 
Intervention 
Sponsor (if any) Modeling Technique and  
Claims Status 
Claims Assessment and 
Credibility 
Evans et 
al.32 
Insulin degludec (lDeg) 
vs. insulin glargine 
(lGLAR) in a basal-bolus 
regimen for patients 
with type 1 diabetes in 
the UK 
The study funded 
by Novo Nordisk 
the manufacturer 
of insulin degludec 
Short-term (12 month) cost per QALY 
model. QALYs estimate by multiplying 
the number of hyperglycemic events 
by a time trade off estimate of the 
disutility per event. Outcomes: 
disutility values utilized for three 
mutually exclusive hypoglycemic 
events: non-severe daytime, non-
severe nocturnal and severe). Results: 
lDeg cost effective vs. lGLAR with base 
case ICER £16,895/QALY with 
incremental QALY 0.0082   
As a short term study there 
is a potential for replicating 
the study claims in a range 
of treating environments if 
the disutility framework 
and scores are applied. No 
evaluable claims presented 
and no protocol to detail 
how the short term results 
might be replicated. This 
might be considered 
important given 
incremental QALY claim 
over lGlar. 
Henry et 
al.33 
Renal denervation 
therapy (RDN) for 
resistant hypertension 
compared to standard 
of care  in the 
Netherlands 
The study was 
funded by 
Medtronic who 
manufacture  the 
Symplicity RDN 
system 
Markov lifetime state transition model 
with 34 health states and 7 clinical 
end points. Outcomes: lifetime cost- 
per-QALY. Results: RDN compared to 
standard of care cost-effective at 
conventional willingness to pay 
thresholds 
With model results 
reported for a lifetime 
horizon there is no basis 
for evaluable claims. 
Lafeuille et 
al.34 
Canagliflozin and 
sitagliptin in type 2 
diabetes patients with 
inadequate glycemic 
control 
The study was 
funded by Janssen 
Scientific Affairs 
who market under 
license 
canagliflozin  
Association between diabetes quality 
measures, blood pressure, low-density 
lipoprotein cholesterol and body 
weight, and health care costs. 
Economic simulation also undertaken 
to evaluate of changes in quality 
measures and incidence of adverse 
events associated with canagliflozin 
and sitagliptin on costs; Outcomes: 
regression analysis from insurance 
claims,  EMRs and quality measure 
metrics to predict cost impacts. 
Results: simulation showed that 
changes in quality metrics and adverse 
event incidence observed in 
comparative  Phase 3 DIA3015 trial 
comparing canagliflozin and sitagliptin 
resulted in PPPY healthcare cost 
reduction that favored canagliflozin    
The authors pointed out 
that a modeled comparison 
based on the DIA3015 trial 
was most appropriate 
given the underutilization 
of canaglifozin in the 
market as approval only 
given in March 2013 
compared to the earlier 
October 2006 approval of 
sitagliptin. A number of 
evaluable hypotheses and 
techniques are suggested 
by the analysis which could 
now be utilized to support 
a retrospective or  
observational evaluation of 
the simulated results. 
Walter & 
Odin35 
Continuous 
subcutaneous 
apomorphine (CSAI) in 
Parkinson’s disease 
(PD) in UK and 
Germany 
The study was 
funded by EVER 
Neuro Pharma the 
manufacturer of 
Dacepton (CSAI) 
Markov lifetime state transition model 
with 12 health states with CSAI vs. 
standard of care, deep brain 
simulation (DBS) and  
levodopa/carbidopa intestinal gel 
(LCIG). Outcomes: costs, QALYs and 
With model results 
reported for a lifetime 
horizon there is no basis 
for evaluable claims. 
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life years (Lys). Results: CSAI a cost-
effective therapy and a possible 
alternative treatment to LCIG or DBS 
in advanced PD 
Xuan et al.36 Bacterial  lysates 
immunostimulant OM-
85 in management of 
respiratory tract 
infections in China 
The study was 
funded by Vifor 
Pharmaceuticals 
the manufacturer 
of OM-85 
Acute treatment 6-month decision 
model comparing OM-85 with and 
without prophylaxis. Outcomes:  costs 
and acute exacerbations or recurrent 
infections. Results: suggest it is a cost-
effective intervention for both chronic 
bronchitis and rhinosinusitis 
With a short time frame 
there is a potential for 
evaluating claims in both 
China and in French, Italian 
and Canadian settings 
where cost-effectiveness 
claimed 
Attard et 
al.37 
Neoadjuvant 
pertuzumab and 
trastuzumab therapy 
for locally advanced, 
inflammatory or early 
HER2-positive breast 
cancer in Canada 
The study was 
funded by 
Hoffman-La Roche 
Ltd the 
manufacturer of 
pertuzumab (on 
acquiring 
Genentech) 
Lifetime cost-per-QALY Markov state 
transition model with three health 
states (event-free, relapsed, dead) 
and a 1-month cycle for a 28-year 
time horizon. Two separate analyses 
utilizing total pCR data from 
NeoSphere and TRYPHAENA trials. 
Outcomes: achieving pCR response, 
event-free and overall survival and 
QALYs Results: the improvement in 
clinical efficacy and favorable cost-
per-QALY against Canadian willingness 
to pay threshold showed pertuzumab 
to be an attractive treatment option  
With model results 
reported for a 28-year time 
horizon there is no basis 
for evaluable claims. 
Lin et al.38 Impact of psychiatric 
relapse and recidivism 
on adults with 
schizophrenia recently 
released from 
incarceration in Florida 
The study was 
funded by Janssen 
Scientific Affairs 
A 3-year Markov state transition 
model. Outcomes: psychiatric 
hospitalizations, infractions, arrests , 
re-incarcerations and direct costs of 
psychiatric hospitalization  and costs 
to the criminal justice system. Results: 
Over 3 years, a relative 20% increase 
in proportion of patients receiving 
antipsychotic treatment  substantially 
reduced total cumulative costs  
With a short time frame 
there is the potential for 
evaluating claims. No 
evaluable claims were 
presented or a protocol to 
support claims assessment 
Home et 
al.39 
Starting insulin 
determir in insulin-
naïve subjects with 
type 2 diabetes in 
Mexico, South Korea, 
India, Indonesia and 
Algeria 
The study was 
funded by Novo 
Nordisk the 
manufacturer of 
insulin determir 
Application of IMS Core Diabetes 
model over a 30-year timeframe to 
project impact of  initiating insulin 
determir.  The assessment included 
also a 1-year analysis to capture 
QALYs. Outcomes:  life expectancy 
clinical, costs and cost-effectiveness . 
Results: initiating insulin determir 
increased life expectancy offsetting 
increased treatment costs, reduced 
diabetes related complications and 
claim for cost effectiveness in all 5 
countries,  
Projections over a 30-year 
time frame have no 
possibility of being 
evaluated and should be 
rejected; the 1-year 
projections have the 
potential to be evaluated 
in these countries 
(assuming data are 
available to support a 
prospective). No evaluable 
claims were proposed or a 
protocol to support claims 
evaluation in target 
populations 
Gupta et 
al.40  
Switching from biphasic 
human insulin 30, 
The study was 
funded by Novo 
Application of IMS Core Diabetes 
model over a 30-year timeframe to 
Projections over a 30-year 
time frame have no 
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insulin glargine, or 
neutral protamine 
Hagedorn to biphasic 
aspart 30 in type 2 
diabetesl (BlAsp 30) in 
India, Indonesia and 
Saudi Arabia 
Nordisk the 
manufacturer of  
BlAsp 30 
project impact of  switching to BlAsp 
30.  The assessment included also a 1-
year analysis to capture QALYs. 
Outcomes:  life expectancy ,clinical, 
costs and cost-effectiveness . Results: 
switching increased life expectancy, 
reduced diabetes related 
complications and was cost-effective 
or highly cost effective in all 3 
countries over 30 years. The 1-year 
analysis showed switching to be cost-
effective, but not as great as the effect 
over 30 years 
 
  
possibility of being 
evaluated and should be 
rejected; the 1-year 
projections have the 
potential to be evaluated 
in these countries 
(assuming data are 
available to support a 
prospective). No evaluable 
claims were proposed or a 
protocol to support claims 
evaluation in target 
populations.   
Huang et 
al.41  
Linaclotide vs. 
lubiprostone in adult 
patients with irritable 
bowel syndrome with 
constipation in the US 
The study funded 
by Ironwood 
Pharmaceuticals 
and Forest 
Research Institute 
the manufacturers 
of linaclotide (with 
rights acquired by 
Allergan in 2015) 
Trial- based (12 week) decision model. 
Outcomes: number of responders, 
QALYs and total costs. Results: 
linaclotide 290mcg QD less expensive, 
greater responsive and more QALYs 
gained than  lubiprostone 8 mcg BID 
based on global assessment of 
symptom relief; for the IBS-QoL 
definition of response linaclotide  had 
lower costs and higher response rates 
for all but one one-way sensitivity 
scenarios.  
With a 12-week timeframe 
(and the possibility of 
extrapolating from the 
clinical trial) there is 
potential for evaluable 
hypotheses to be 
evaluated. No evaluable 
claims were proposed or a 
protocol to support claims 
evaluation in target 
populations 
O’Day et 
al.42 
Natalizumab vs. 
fingolimod in relapsing 
remitting multiple 
sclerosis in Sweden 
The study funded 
by Biogen Idec Inc 
the manufacturer 
of batalizumab 
Two-year decision model. Outcomes: 
MS relapses avoided, cost per relapse 
avoided. Results: natalizumab 
dominates fingolimod 
With a  2-year timeframe 
there is  potential for 
evaluable hypotheses to be 
evaluated. No evaluable 
claims were proposed or a 
protocol to support claims 
evaluation in target 
populations 
Sung et al.43 Posaconazole vs. 
fluconazole or 
itraconazole (FLU/ITRA) 
in prevention of 
invasive fungal diseases 
in US neutropenic 
patients 
The study was 
funded by Merck 
the manufacturer 
of posaconazole 
Update of trial based incremental 
cost-effectiveness model in 100 day 
trial plus follow-up framework. 
Outcomes: efficacy, IFD related 
mortality, death from other causes 
and direct medical costs. Results: 
posaconazole yielded fewer IFD 
events and lower overall costs    
With a short time frame 
there is the potential for 
evaluating claims. No 
evaluable claims were 
presented or a protocol to 
support claims assessment 
Nazir et al.44  Pharmacological 
treatments for 
overactive bladder 
focusing on mirabegron 
as first in-class selective 
ẞ3 -adrenoceptor  
agonist from a UK NHS 
perspective 
The study was 
funded by Astellas 
Pharma Europe 
Ltd the 
manufacturers of  
mirabegron 
Markov model with monthly cycle 
length and time horizon of up to 3 
years to compare 2 different 
sequencies of up to 3 lines of oral 
therapy. Outcomes: (i) number of 
patients with controlled symptoms 
(no incontinence episodes and <8 
micturitions per 24 h); (ii) patients 
with no incontinence episodes per 24 
With a 1-year timeframe 
there is potential for 
evaluable hypotheses to be 
evaluated. No evaluable 
claims were proposed or a 
protocol to support claims 
evaluation in target 
populations 
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hours; and (iii) patients with <8 
micturitions per 24 h. Results: new 
treatment sequence of including 
recently approved agent as 3rd line 
before considering other treatment 
options over a 1-year time horizon 
associated with greater number of 
controlled patients and fewer 
incontinence episodes  but higher 
costs compared to standard treatment 
sequence.   
Zachariah & 
Samnaliev45  
Echo-based screening 
of rheumatic heart 
disease in children 
The study funded 
by National Heart, 
Lung, and Blood 
Institute Career 
Development 
Award 
Population-based Markov 2-stage 
screening model comparing screening 
to no screening running over 40 years. 
A yearly time cycle comparing societal 
costs and QALYs between current 
practice of routine clinical exam 
detection and population based rapid 
echocardiography rsingle scereening 
followed by full echo in screen 
positive opatients. Outcomes: costs, 
QALYs and ICER per QALY. Results: 2-
stage screening and secondary 
prophylaxis may achieve modestly 
improved outcomes at a lower costs 
Projections over a 40-year 
time frame have no 
possibility of being 
evaluated and should be 
rejected. . No evaluable 
claims were proposed or a 
protocol to support claims 
evaluation in target 
populations 
Toor et al.46 Infliximab, 
adalimumab, and 
golimumab in 
moderately to severely 
active ulcerative colitis 
The study was 
funded by Janssen 
Inc Canada the 
manufacturers of 
golimumab 
One-year Markov model with 8-week 
induction period and 22 subsequent 2-
week cycles up to 1-year for three 
tumor necrosis factor inhibitors 
(infliximab, adalimumab, and 
golimumab) in comparison to 
conventional therapy.. Outcomes: 
short-term costs per sustained 
remission and sustained response. 
Results: Lowest costs of one full year 
remission and response for 
golimumab 100mg followed by 
golimumab 50mg  
With a one year time frame 
potential for evaluating 
claims. No evaluable claims 
were presented or a 
protocol to support claims 
assessment in target 
populations 
Penn et al.47 Impact of implementing 
a multiple 
inflammatory 
biomarker –based 
approach to identify, 
treat and reduce 
cardiovascular risk 
The study 
supported by 
Cleveland Heart 
Lab Inc. a 
manufacturer of 
cardiovascular 
biomarkers 
Modeling of change in number of 
events and costs after routine 
implementation of routine risk-
stratification with multiple 
inflammatory biomarker approach. 
Outcomes: estimated events for a one 
million member health plan over 5-
years (fatal MI and IS events( and cost 
savings. Results: substantial 
prospective events avoided and cost 
savings over 5-years 
With a shorter time frame 
than 5 years, there is the 
potential for evaluating 
claims. No evaluable claims 
were presented or a 
protocol to support claims 
assessment in target 
populations. 
Hofmarcher 
& Borg48 
Ferric carboxymaltose 
in iron deficient 
patients with chronic 
The study was 
supported by Vifor 
Pharma Nordiska 
Twenty-four week cost per QALY 
model (vs. placebo). Outcomes: direct 
medical costs and QALYs. Results: ICER 
With a short time frame 
there is the potential for 
evaluating claims. No 
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heart failure in Sweden AB the 
manufacturers of 
ferric 
carboxymaltoser 
at €8,194/QALY below notional 
Swedish WTP threshold of  
€53,300/QALY.    
evaluable claims were 
presented or a protocol to 
support claims assessment 
Kuwabara et 
al.49 
Simeprevir with 
peginterferon (PR) and 
ribavirin vs. telaprevir 
with ribavarin, PR alone 
or no treatment in 
treatment-naïve 
chronic hepatitis C 
genotype 1 patients in 
Japan 
The study was 
supported by 
Janssen 
Pharmaceutica NV 
the manufacturer 
of simeprevir 
Markov model to map the progression 
of HCV to estimate average life years 
and lifetime average costs. Outcomes: 
ICERs and incremental costs and life 
years. Results: SMV with PR compared 
to telaprevir with PR and PR alone was 
dominant with life years gained at a 
lower cost 
With model results 
reported for subject 
lifetimes there is no basis 
for evaluable claims. 
Laires et 
al.50 
Adding ezetimibe to 
atorvastatin vs. 
switchning to 
rosuvastatin therapy 
for high cardiovascular 
risk patients in Portugal 
The study was 
supported by 
Merck Sharp & 
Dohme the 
manufacturer of 
the combination 
product 
ezetimibe/atorvas
tatin  
Lifetime cost-per-QALY Markov model 
with annual cycles (up to age 100 
years). Outcomes: lifetime costs and 
life years/QALYs. Results: base case 
ICER estimated at €16,465. As this is 
below Portuguese WTP threshold of 
€30,000/QALY adding ezetimibe vs. 
switching to rosuvastatin  is cost-
effective 
With model results 
reported for subject 
lifetimes there is no basis 
for evaluable claims. 
Huetson et 
al.51  
Once-daily GLP-1 
receptor agonist 
lixisenatide vs. bolus 
insulin both in 
combination with basal 
insulin for type 2 
diabetes in Norway 
The study was 
supported by 
Sanofi the 
manufacturer of 
lixisenatide 
Application of IMS Core Diabetes 
model to project lifetime cost-per-
QALY. Subjects assumed to receive 
combination treatment with basal 
insulin, lixisenatide or bolus insulin for 
3 years followed by intensification of 
basal-bolus insulin for their remaining 
lifetime. Outcomes: weight loss, 
lifetime healthcare costs and QALYs. 
Results: lixisenatide reduced lifetime 
healthcare costs and increased QALYs. 
ICER below Norwegian willingness to 
pay threshold. 
With model results 
reported for subject 
lifetimes there is no basis 
for evaluable claims.  
Muser et 
al.52 
Paliperidone palmitate 
vs. oral antipsychotics 
in schizophrenia 
The study was 
supported by 
Janssen Scientific 
Affairs the 
manufacturer of 
paliperidone 
palmitate 
Trial-based cost-outcomes model (15 
months) PRIDE. Objectives: to assess 
comparative ICER for costs (not 
collected in trial) incurred to first 
treatment failure (healthcare or 
criminal justice system) comparing 
paliperidone palmitate with 
antipsychotics. Results: ICERs favored 
paliperidone palmitate ranging from 
$17,391 per psychiatric hospitalization 
(HC) or criminal justice system (CJS) 
event avoided to $77,731 per patient 
that avoided any incarceration 
compared to oral antipsychotic group. 
Costs for HC or.CJS events avoided 
offset 25% of the greater drug cost 
with paliperidone palmitate. 
The relatively short time 
frame (and the ability to 
modify timeframe) there is 
a potential for generating 
evaluable claims for a 
range of post-incarceration 
settings and CJS costs. No 
evaluable claims were 
provided..  
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Cure et al.53 Sofosbuvir plus ribavirin 
with or without 
pegylated interferon for 
chronic hepatitis C in 
Italy 
The study was 
supported  by 
Gilead Sciences 
the manufacturer 
of sofosbuvir 
Markov  cost-per-QALY model with 
subjects followed (cohort of 10,000) 
until reached 80 years of age. Based 
on models published by Southampton 
Health Technology Assessment Centre 
for NICE. Outcomes: overall for the for 
the 6 HIV genotype groups analyzed 
the SOF-based regimens gave a 
favorable cost-effectiveness profile 
versus standard of care 
With model results 
reported for subject 
lifetimes there is no basis 
for evaluable claims. 
Meier et 
al.54 
Updated analysis of 
quadrivalent influenza 
vaccination versus 
trivalent influenza 
vaccination  in at-risk 
adults and the elderly 
in the UK  
The study 
supported by 
GlaxoSmithKline 
Biologicals the 
manufacturer of 
QIV 
Update of a lifetime, multi-cohort 
static Markov model run in 1-year 
cycles until youngest patients at entry 
achieved age of 100 years. Outcomes: 
influenza cases avoided, 
hospitalizations and deaths avoided , 
costs and QALYs compared to TIV. 
Results: QIV was estimated to be cost-
effective in 68% of simulation with a 
cost-per-QALY threshold of <£20,000.   
With model results 
reported for subject 
lifetimes (simulated to age 
100 years) there is no basis 
for evaluable claims. 
Peng et al.55 DTG+ABC/3T versus 
EFV/TDF/FTC for first 
line treatment of HIV-1 
in the US 
The study was 
supported  by 
Bristol-Myers 
Squibb who 
acquired DTG 
from 
GlaxoSmithKline 
 
Lifetime discrete event simulation 
model for lifetime CD$ counts, clinical 
events, treatment switching and 
death. Outcomes: lifetime discounted 
medical costs, QALYs and ICERs. 
Results: DTG+ABC/3TC resulted in 
higher costs and only slightly 
increased QALYs with an ICER that 
exceeded standard cost-effectiveness 
threshold. Incremental benefits may 
not be worth incremental costs. 
With model results 
reported for subject 
lifetimes there is no basis 
for evaluable claims. 
Pennington 
et al.56 
Selective internal 
radiation therapy using 
yttrium -90 resin 
microspheres in 
inoperable colorectal 
liver metastases versus 
best supporting care  in 
the UK 
The study was 
supported by 
Sirtex Medical Ltd 
the manufacturer 
of yttrium -90 
resin 
microspheres  
State-transition, trial based lifetime 
cost-per-QALY model with a daily 
cycle. Outcomes: QALYs per life year 
gained, discounted costs and adverse 
events. Results: compared to best 
supportive care SIRT using yttrium -90 
resin microspheres is a clinically 
effective and cost-effective option 
Given the anticipated life 
expectancy of target 
patients there is the 
potential to develop 
evaluable hypotheses to 
evaluate outcomes in UK 
and other treatment 
settings. No evaluable 
claims or a protocol for 
possible evaluations were 
proposed. 
Gu et al.57 Saxagliptin vs. 
glimepride as second 
line addred to 
metformin in type 2 
diabetes in China 
The study was 
supported by 
AstraZeneca who 
(in collaboration 
with Bristol-Myers 
Squibb) is the 
manufacturer of 
saxagliptin 
Application of Cardiff diabetes model 
to simulate disease progression and 
long-term impacts over a 40-year 
period. Outcomes: mcosts, events 
incidence and QALYs. Results: 
Saxagliptin + metformin more cost-
effective with fewer adverse effects 
With results reported for a 
40-year timeframe there 
are no evaluable claims. 
Rajagopalan 
et al.58 
Lurasidone vs. 
quetiapine XR in bipolar 
The study was 
supported  by 
Three-month trial-based cost-
effectiveness model. Outcomes 
With a 3-month time 
frame, there is the 
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depression Sunovion 
Pharmaceuticals 
the manufacturer 
of lurasidone 
measure percentage of patients 
achieving remission (MADRAS total 
score ≤12 by weeks 6-8). Outcomes: a 
greater percentage of lurasidone XR 
patients achieved remission, with 
lurasidine havig a 86% probability of 
being cost-effective. . 
potential for evaluable 
claims to evaluate cost-
effectiveness in bipolar 
depression and to report 
results to decision makers. 
No evaluable claims were 
proposed although 
author’s pointed to the 
possibility of product 
impact assessments over 
longer periods and in real 
world settings. 
Westerhout 
et al.59 
Simeprevir used with. 
pegintrerferon + 
ribavirin in 
management of 
genotype 1 hepatitis C 
in the UK 
The study was 
supported by 
Jansen EMEA the 
manufacturer of 
simeprevir 
A 2-phase cost-utility model  with 
therapy efficacy captured in first 
phase and a second Markov phase of 
long-term post-treatment to capture 
lifetime outcomes. Health state 
utilities were the principal outcome. 
Results: SMV+PR a superior treatment 
option 
With results reported for a 
40-year timeframe there 
are no evaluable claims. 
Maruszczak 
et al.60  
Flingolimod vs. 
dimethyl fumarate  in 
highly active relapsing-
remitting multiple 
sclerosis in England 
The study was 
supported by 
Novartis 
Pharmaceuticals 
the manufacturer 
of  flingolimod 
Lifetime cost-per-QALY cohort Markov 
model to determine cost-utility of oral 
DMTs in HA RRMS, to include 
conversion to secondary progressive 
MS (SPMS) involving 21 states. The 
Markov structure was based on 
models used in all NICE single 
technology appraisal submissions for 
DMTs in RRMA.Outcomes: QALYs and 
costs over a lifetime horizon modeled 
as 50 years. Results: flingolimod is 
cost-effective in HA RRMS following 
the introduction  of DMT to the UK 
market., 
With results reported for a 
50-year timeframe there 
are no evaluable claims. 
Thibault et 
al.61 
Memantine ER + 
cholinesterase inhibitor 
monotherapy vs. 
memantine ER as 
monotherapy in 
moderate-to-severe 
Alzheimer’s [sic] type in 
the US 
The study was 
supported by 
Forest Research 
Group (affiliate of 
Actavis). Actavis is 
the manufacturer 
of memantine ER 
A 3 year cost-per-QALY evaluation 
using a modified version of the AHEAD 
II discrete event simulation model. 
Outcomes included (i) clinical 
impairment, (ii) health related QoL, 
mean time in institution, mean time 
with SIB severity, mean time without 
severe and mean time on 
antipsychotics, and (iii) direct medical 
costs and caregiver costs. Results: 
over 3-years memantine ER combined 
with cholinesterase inhibitors gave 
better clinical outcomes and lower 
costs, with a favorable  ICER per QALY 
gained.  
As a short term study there 
is potential, as the authors 
indicate, for prospective 
observational studies  to 
generate more accurate 
projections of disease 
progression and treatment 
effectiveness. No evaluable 
propositions were 
presented. To support 
claims for clinical and cost-
effectiveness..  
Deng et al.62 Cost-effectiveness of 
exenatide vs. insulin 
glargine in Chinese type 
No funding 
sources reported 
Application of Cardiff diabetes model 
with a 40-year timeframe. Outputs: 
macrovascular and microvascular 
With results reported for a 
40-year timeframe there 
are no evaluable claims.  
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2 diabetes patients 
inadequately controlled 
by oral therapies 
complications, diabetes-specific 
mortality, costs and QALYs Results: 
exenatide as an add-on therapy is 
cost-effective compared to insulin 
glargine. 
Muduma et 
al.63 
Budget impact 
comparison of Advagraf 
versus Prograf  in renal 
transplantation as 
primary 
immunosuppressive 
medication 
The study was 
supported by 
Astellas Pharma 
EMEA Ltd the 
manufacturer of  
Advagraf 
Five-year budget impact cost-
adherence model structured as a 
decision tree followed by a 4-state 
Markov model with monthly cycle 
length. Outcomes: costs, antibody-
mediated rejection and graft Results: 
over five years a cost saving with 
Advagraf from a UK perspective in 
renal transplant recipients] 
As a short term budget 
impact model, there is the 
potential for developing 
empirically assessable 
claims in a time frame of 
less than 5 years.  No 
evaluable claims or a 
protocol for evaluating 
claims were presented. 
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